Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres
Sign Up to like & getrecommendations! Published in 2020 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-020-01086-9
Abstract: The combination of bortezomib, cyclophosphamide and dexamethasone (CyBorD or VCD) has been evaluated using different protocols in multiple myeloma (MM). Most of these studies employed twice weekly bortezomib at 1.3 mg/m (days 1, 4, 8,… read more here.
Keywords: response; transplant; disease; cybord ... See more keywords
Chalazion in a patient with multiple myeloma treated with bortezomib
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Case Reports"
DOI: 10.1136/bcr-2022-251077
Abstract: We present a case of a woman in her early 60s with multiple myeloma who, while undergoing treatment with cyclophosphamide, bortezomib and dexamethasone (CyBorD), noticed a whitish nodular swelling on the eyelid. This occurred after… read more here.
Keywords: myeloma; chalazion patient; patient multiple; cybord ... See more keywords
Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-130364
Abstract: Introduction: Autologous stem cell transplant (ASCT) is a very effective treatment in AL amyloidosis. However, its role is challenged by novel, powerful, non-transplant therapy, also due to the potentially high treatment-related mortality (TRM) that requires… read more here.
Keywords: response cybord; response; treatment; cybord ... See more keywords
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2020002219
Abstract: Autologous stem cell transplant (ASCT) is highly effective in selected patients with light chain (AL) amyloidosis. Bortezomib, preceding or following ASCT, improves responses. Satisfactory responses, including at least a partial response, very good partial response… read more here.
Keywords: response; cybord; stem cell; amyloidosis ... See more keywords
Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.8035
Abstract: 8035 Background: LYRA is a community practice-based, phase 2, single-arm study (NCT02951819) evaluating DARA + CyBorD as an immunomodulatory drug-sparing regimen in MM. The primary analysis demonstrated the safety and efficacy of DARA + CyBorD… read more here.
Keywords: therapy; maintenance; cybord; study ... See more keywords